Displaying 1 publication

Abstract:
Sort:
  1. Herr K, Berk M, Huang WL, Kato T, Lee JG, Ng CG, et al.
    Neuropsychopharmacol Rep, 2025 Mar;45(1):e70007.
    PMID: 40011065 DOI: 10.1002/npr2.70007
    AIM: Anhedonia is a key symptom of major depressive disorder (MDD), however, its burden in patients with MDD is not well understood. We aimed to assess the impact of anhedonia on health-related quality of life (HRQoL), health-care resource utilization (HRU), and work productivity in subjects with MDD and anhedonia (MDD-ANH) compared to subjects with MDD without ANH (MDD non-ANH).

    METHODS: A cross-sectional web-based survey was conducted across six countries/territories. Adult participants were categorized as MDD-ANH, MDD non-ANH, and General Population based on self-reported MDD diagnosis, Patient Health Questionnaire (PHQ-9), and Snaith-Hamilton Pleasure Scale (SHAPS). Multivariate/generalized linear regression modeling (GLMs) and mediation analysis were used to assess anhedonia's impact on HRQoL/function, HRU, and work productivity.

    RESULTS: Among 11 383 respondents, 20.1% were identified with MDD (MDD-ANH: 12.7%; MDD non-ANH: 7.3%) and 79.9% as General Population. Subjects with MDD-ANH, compared with MDD non-ANH demonstrated significantly worse or lower sexual functioning, HRQoL (RAND mental/physical component summary, health state utility (EuroQol) Index scores, all p 

Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links